Clinical Analysis of the Patients With Cavitary Pulmonary TB and Endobronchial TB in the PPM-UUH Cohort
NCT ID: NCT03822156
Last Updated: 2019-06-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2010-01-01
2018-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Co-Infection of NTM in Patients With Smear Positive Pulmonary TB
NCT00567151
Ultralow Dose Computed Tomography in High-risk Drug-resistant Tuberculosis Contacts
NCT02454738
Thin Bronchoscope and Virtual Bronchoscopic Navigation System for Tuberculosis
NCT03802812
LIFE-TB ; Long-Term Impacts on Lung Health and Life After Tuberculosis in Korea
NCT06946784
Multi-Drug Resistant Tuberculosis in Korea
NCT00341601
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However, there are few studies on this, so it is not known how long the infectivity persists, whether there is a correlation with the number of cavities or the size of the cavities between persistence of infectivity.
Meanwhile, endobronchial TB is known also to be highly infectious, unlike simple pulmonary TB.
It is not known how long infectivity can persist after the administration of anti-TB medication, and whether there is any difference in persistence of infectivity regarding the clinical characteristics of endobronchial TB.
In this study, investigators will analyze the retrospective data analysis of UUH-PPM Cohort, a cohort of PPM project patients in the Ulsan University Hospital (UUH).
The PPM project is a "Private-Public Mix project" for the eradication of tuberculosis from Korea, which the Korean government and private medical institutions have been conducting since 2007.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cavitary Pulmonary Tuberculosis
The patients who are diagnosed with the cavitary pulmonary tuberculosis
Observation of AFB smear/culture
Observation of the patients from group for their AFB smear/culture results
Endobronchial Tuberculosis
The patients who are diagnosed with the endobronchial tuberculosis
Observation of AFB smear/culture
Observation of the patients from group for their AFB smear/culture results
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observation of AFB smear/culture
Observation of the patients from group for their AFB smear/culture results
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The patient who has the cavitary pulmonary TB
1. Aged 18 years and older
2. The patient who has the endobronchial TB through bronchoscopy
Exclusion Criteria
2. Any Malignant patient
3. Patients with bacterial or viral or fungal pneumonia based on the judgment of the attending physician
4. Patients who had a history of any pulmonary cystic lesion such as infected bulla, bullous emphysema
5. Patients who were diagnosed with pulmonary fungal infection or previous its history or any documented culture of the fungus from a bronchial sample including sputum
6. Patients who were diagnosed with bronchiectasis
7. Patients who were diagnosed with NTM-PD (non-tuberculous mycobacterial pulmonary disease) or any documented culture of NTM from a bronchial sample including sputum
8. Patients who were diagnosed with connective tissue disease such as Wegener's granulomatosis, SLE
9. Patients who were diagnosed with TB destroyed lung
10. Patients who were diagnosed with congenital lung disease such as Congenital Cystic Adenomatoid Malformation (CCAM), pulmonary sequestration
11. Patients who were diagnosed with interstitial lung disease such as Lymphangioleiomyomatosis (LAM), idiopathic pulmonary fibrosis (IPF)
12. Patients who were diagnosed with culture-negative pulmonary TB
13. Patients who did not take anti-TB medication more than twice a week on average
14. Patients who were diagnosed with sarcoidosis
15. Patients who were diagnosed with paragonimiasis
16. Patients who were diagnosed with pulmonary thromboembolism due to excluding pulmonary infarction
17. The patient who did not consent
18. Patients who were diagnosed with MDR/XDR TB through AFB culture
B. Endobronchial TB Group
1. Age \< 18 years
2. Patient who was not consented
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ulsan University Hospital
OTHER
University of Ulsan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kwang Won Seo
Associate professor, division of pulmonology, dept. of internal medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kwang Won Seo, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Ulsan University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ulsan University Hospital, 877 Bangeojin Sunwhando-ro
Ulsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KCT0003707
Identifier Type: OTHER
Identifier Source: secondary_id
UUlsan
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.